Similar articles for PMID: 37607302

Year	Number of Results
2010	1
2011	1
2012	2
2013	2
2014	4
2015	8
2016	12
2017	9
2018	9
2019	8
2020	18
2021	18
2022	17
2023	16
2024	1

1

CYP2C19 Loss-of-Function Variants Associated With Long-Term Ischemic Stroke Events During Clopidogrel Treatment in the Chinese Population.

Wu P, Liu Z, Tian Z, Wu B, Shao J, Li Q, Geng Z, Pan Y, Lu K, Wang Q, Xu T, Zhou K. Wu P, et al. Clin Pharmacol Ther. 2023 Nov;114(5):1126-1133. doi: 10.1002/cpt.3028. Epub 2023 Sep 5. Clin Pharmacol Ther. 2023. PMID: 37607302

2

Analysis of CYP2C19 genetic variants with ischaemic events in UK patients prescribed clopidogrel in primary care: a retrospective cohort study.

Pilling LC, Türkmen D, Fullalove H, Atkins JL, Delgado J, Kuo CL, Kuchel GA, Ferrucci L, Bowden J, Masoli JAH, Melzer D. Pilling LC, et al. BMJ Open. 2021 Dec 13;11(12):e053905. doi: 10.1136/bmjopen-2021-053905. BMJ Open. 2021. PMID: 34903548 Free PMC article.

3

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.

Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, Bell M, Bae JH, Jeong MH, Chavez I, Gordon P, Abbott JD, Cagin C, Baudhuin L, Fu YP, Goodman SG, Hasan A, Iturriaga E, Lerman A, Sidhu M, Tanguay JF, Wang L, Weinshilboum R, Welsh R, Rosenberg Y, Bailey K, Rihal C. Pereira NL, et al. JAMA. 2020 Aug 25;324(8):761-771. doi: 10.1001/jama.2020.12443. JAMA. 2020. PMID: 32840598 Free PMC article. Clinical Trial.

4

Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.

Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, Pan Y, Liu L, Wang D, Wang C, Meng X, Xu J, Wang Y; CHANCE investigators. Wang Y, et al. JAMA. 2016 Jul 5;316(1):70-8. doi: 10.1001/jama.2016.8662. JAMA. 2016. PMID: 27348249 Clinical Trial.

5

Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

Xie X, Johnston SC, Wang A, Xu Q, Bath PM, Pan Y, Li H, Lin J, Wang Y, Zhao X, Li Z, Jiang Y, Liu L, Xu A, Jing J, Meng X, Wang Y. Xie X, et al. JAMA Netw Open. 2023 Jun 1;6(6):e2317037. doi: 10.1001/jamanetworkopen.2023.17037. JAMA Netw Open. 2023. PMID: 37279000 Free PMC article. Clinical Trial.

6

Ticagrelor Aspirin vs Clopidogrel Aspirin in CYP2C19 Loss-of-Function Carriers With Minor Stroke or TIA Stratified by Risk Profile.

Wang A, Meng X, Tian X, Zuo Y, Bath PM, Li H, Xie X, Jing J, Lin J, Wang Y, Zhao X, Liu L, Li Z, Jiang Y, Xu J, Wang F, Chen W, Cao M, Li J, Wang Y. Wang A, et al. Neurology. 2023 Jan 31;100(5):e497-e504. doi: 10.1212/WNL.0000000000201454. Epub 2022 Dec 19. Neurology. 2023. PMID: 36535779 Free PMC article.

7

CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease.

Patel PD, Vimalathas P, Niu X, Shannon CN, Denny JC, Peterson JF, Chitale RV, Fusco MR. Patel PD, et al. J Stroke Cerebrovasc Dis. 2021 Feb;30(2):105464. doi: 10.1016/j.jstrokecerebrovasdis.2020.105464. Epub 2020 Nov 24. J Stroke Cerebrovasc Dis. 2021. PMID: 33246208 Free PMC article.

8

CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.

Lin J, Mo Y, Cai D, Mao D, Fu H, Wei D. Lin J, et al. Ann Palliat Med. 2021 Dec;10(12):12171-12180. doi: 10.21037/apm-21-2905. Ann Palliat Med. 2021. PMID: 35016407 Free article.

9

Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.

Guo B, Tan Q, Guo D, Shi Z, Zhang C, Guo W. Guo B, et al. J Vasc Surg. 2014 Oct;60(4):993-1001. doi: 10.1016/j.jvs.2014.03.293. Epub 2014 May 28. J Vasc Surg. 2014. PMID: 24877854 Free article.

10

Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.

Tomek A, Matʼoška V, Frýdmanová A, Magerová H, Šrámek M, Paulasova-Schwabová J, Růžičková T, Janský P, Šarbochová I, Hadačová I, Kaplan V, Lacinová Z, Táborský L, Serebruany V. Tomek A, et al. Am J Ther. 2018 Mar/Apr;25(2):e202-e212. doi: 10.1097/MJT.0000000000000416. Am J Ther. 2018. PMID: 29509167

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year